tell Healthcare Awarded National Kidney Foundation's K/DOQI Distinguished Partner Award

to focus
exclusively on kidney and kidney-related disorders.

circulatory vascular

About K /DOQI
The National Kidney Foundation's Kidney Disease Outcomes Quality
Initiative (K/DOQI) provides evince-based clinical practice guidelines
developed by volunteer physicians and health care providers for all phases of
kidney disease and related complications, from diagnosis to monitorinandmanagement .

cardiovascular vascular

groups vascular

heart cardiac

D."
According to the guidelines, cardiovascular disease (CVD) is the leading
cuse of death among dialysis patients and treatment for dialysis patients
with CVD is not as efective as it is in the general population. For more information, please visit
http://www.

anomalies health

is a biopharmaceutical company focused on developing a new drug
for the treatment of cardiovascular diseases where the growth of new
blood vessels can improve the outcome for patients with these
diseases. Without this guidee , made
possible through the support of Satellite Healthcare, the medical community
would still be seeking the best methods for managing the leading cause of
death among dialysis patien," said John Davis, chief executive officer of
the NKF..

Diseases or disorders of the heart or circulatory system.

pediatric blood

concerning blood

"Until now, there have been no gdelines for the treatment of
cardiovascul disease in dialysis patients.org.

preventive iafrica

Horizon Ridge Parkway
Henderson, Nevada 89012

Main Telephone: 702-248-1174

Website: www.

answers groups

com

Ticker: CVBT(OTCBB)

Type of
Organization: Public
Investor Relations Agency

Industry: Health: Biotechnology

Key Executives: President: Daniel C Montano
Vice President/COO/Director: Thomas Stegmann M.S
Vice President/Director/CFO: Mickael A Flaa

Media Contact
Contact: Jodi Mack
Phone: (702) 248-1174
Email: pr@cvbt.com

S.com.

diseases circulatory

heart child

It's drug candidate, Cardio Vascu-Grow(TM), is designed to
facilitate the growth of new blood vessels in the heart and other
tissues with an impaired vascular system. For more
information , please visit http://www.

disease families

Business Editors

----The Business: CardioVascular BioTherapeutics ,
Inc.

Company: CardioVascular BioTherapeutics, Inc

Headquarters
Address: 1700 W.Company Recognized for Ongoing Commitment to Improving Chronic idney Disease
Patient Outcomes

MOUNTAINIEW, Calif, 5 -- Satellite Healthcare , Inc.
"eare honored to be chosen by NKF to receive this prestigious award
based on our commitment to rsearch, innovation and high standards related to
the treatment of CKD," said Norman S.

preventive anomalies

Satellite Healthcare, wit
headquarters in Mountain View, CA., includes: Satellite Laboratory Services,
providing laboratory services to dialysis facilities throughout the U.

disease pediatric

president, David Warnock, M.satellitehealth .

families blood

cvge. Coplon chairman and founder of
Satellite Healthcare. The
guidelines, which were published as a supplement to the April 2005 issue of
the American Journal of Kidney Diseases, go on to offer treatm and research
recommendations specifically tailored to CVD idialysis paents
Key ings from the CVD guidelines include:

* Dialysis patients are more prone to side-efcts of CVD treatment
* Pediatric chronic dialysis patients are 1,000 times more likelyto
die from CVD than the general pediatric population
* All dialysis units should have on-site capability forernal
cardiac defibrillation, such as autoc external defibrillars
* Predialysis and postdialysis blood pressure goals should b < 140/90
mm Hg and < 130/80 mm Hg, respectively
* Dialysis patients oftehave CVD-related risk factors, including
anemia, hyperparathyroidism, hypoalbumi nemia and chr inflammation, among others .

blood vascular

"This generosity represents just the atest example of Satellite
Healthcare's commitment to improving the lives of the CKD patient population.

concerning surgery

, a
leader in the field of kidney disease, today announced that the company has
been selected to receive the National Kidney Foundation's (NK Kidney Disease
Outcomes Quality Initiative (K/DOQI) Distinguished Partner Award. In keeping with our mission, we
believe these important guidelines wilhelp improve patient outcomes lead
to muchneeded research in the area of CVD in patietn dialysis.

cardiac groups

This award
is intended to recognize an organization that has demonstrated an ongoing
commitment to improing clinical and quality of life outcomes or patients
with chronic kidney disease (CKD).
About Satellite Healthcare
Satellite Healthcare was founded in l974 by Norman Coplon, M.

disorders questions

, will
present Satellite Healthcare with the award at the organization's 2005 Spring
Clinical Meetings' President's Dinner, being held this evening.

disorders pediatric

We are pleased to honor the company with our K/DOQI Distinguished Partner
Award.

patients groups

Company Profile for CardioVascular BioTherapeutics Inc.

"We are particularly proud of our role as primry
development sponsor for NKF's recently published K/DOQI guideline,
Cardiovascular Disease in Dalysis Patients .

pediatric disorders

K/DOQI expands the Dialysis Outcomes Quality Initiative or DOQI, a
project begun by the Nonal Kidney Foti1995 and recognized
throughout the world for improvi the care of dialysis patients.

diseases pediatric

kdoqi.

families preventive

;
Satellite Research, sponsoring research through intramural clinical research
and extramural research grants; Satellite Capital, pviding venture capital
to early-stage heath care companies; Satellite Dialysis, offering muiple
dialysis programs to patients with kidney disease in Northern California; and
WellBoun the first healthcare services company dedicated exclusively to the
care of home dialysis patints.